-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK: AREXVY RECOMMENDED FOR ADULTS AGED 50-59 AT INCREASED RISK FOR SEVERE RSV DISEASE BY US ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

Reuters·04/16/2025 21:11:00

Please log in to view news